Evaluating efficacy of bacteriophage therapy against Staphylococcus aureus infections using a silkworm larval infection model.
Evaluating efficacy of bacteriophage therapy against Staphylococcus aureus infections using a silkworm larval infection model.
复制标题
DOI：
10.1111/1574-6968.12220
复制
发表时间：
2013-10
影响因子：
2.1
通讯作者：
Iyo Takemura-Uchiyama;Jumpei Uchiyama;Shin-ichiro Kato;Tetsuyoshi Inoue;Takako Ujihara;N. Ohara;M. Daibata;S. Matsuzaki
中科院分区：
文献类型：
--
作者：
Iyo Takemura-Uchiyama;Jumpei Uchiyama;Shin-ichiro Kato;Tetsuyoshi Inoue;Takako Ujihara;N. Ohara;M. Daibata;S. Matsuzaki
家蚕幼虫是目前公认的高等哺乳动物评价抗生素效果的替代模式动物。在这项研究中，我们研究了噬菌体（噬菌体）治疗的疗效，利用抗菌药物，对金黄色葡萄球菌感染，使用蚕幼虫感染模型。两种新分离的葡萄球菌噬菌体S25-3和S13 ′被用作治疗性噬菌体候选物。根据它们的形态和主要衣壳蛋白的N-末端氨基酸序列，它们被分配到两个不同的裂解性噬菌体属，Twort样和AHJD样病毒。这两种菌株的寄主范围广，溶菌活性强，具有一定的防腐性。单独给药这些化合物对家蚕幼虫没有不良影响。在家蚕幼虫感染模型中，病毒感染后10 min、6 h、12 h和24 h均表现出明显的生命延长作用。在家蚕幼虫模型中的这种噬菌体效应与在小鼠模型中的治疗效果几乎相同。这些结果表明，噬菌体S25-3和S13'适合作为治疗候选物，并且家蚕幼虫模型对于评价噬菌体治疗以及小鼠模型是有效的。
Silkworm larva has recently been recognized as an alternative model animal for higher mammals to evaluate the effects of antibiotics. In this study, we examined the efficacy of the bacteriophage (phage) therapy, which harnesses phages as antibacterial agents, against Staphylococcus aureus infections, using the silkworm larval infection model. Two newly isolated staphylococcal phages, S25-3 and S13', were used as therapeutic phage candidates. They were assigned to two different lytic phage genera, Twort-like and AHJD-like viruses, based on their morphologies and the N-terminal amino acid sequences of the major capsid proteins. Both had a broad host range and strong lytic activity and showed preservative quality. Administration of these phages alone caused no adverse effects in the silkworm larvae. Moreover, the viruses showed life-prolonging effects in the silkworm larval infection model 10 min, 6 h, 12 h, and 24 h following infection. Such phage effects in the silkworm larval model were almost paralleled to the therapeutic efficacies in mouse models. These results suggest that phages S25-3 and S13' are eligible as therapeutic candidates and that the silkworm larval model is valid for the evaluation of phage therapy as well as mouse models.